Page 2113 - Williams Hematology ( PDFDrive )

2088 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2089

Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281(9):806– 105. Cannon CP, McCabe CH, Borzak S, et al: Randomized trial of an oral platelet glyco-
810, 1999. protein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome:
77. Chen DK, Kim JS, Sutton DM: Thrombotic thrombocytopenic purpura associated Results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation
with ticlopidine use: A report of 3 cases and review of the literature. Arch Intern Med 97(4):340–349, 1998.
159(3):311–314, 1999. 106. Bhatt DL, Chew DP, Hirsch AT, et al: Superiority of clopidogrel versus aspirin in
78. Bennett CL, Connors JM, Carwile JM, et al: Thrombotic thrombocytopenic purpura patients with prior cardiac surgery. Circulation 103(3):363–368, 2001.
associated with clopidogrel. N Engl J Med 342(24):1773–1777, 2000. 107. Bassler N, Loeffler C, Mangin P, et al: A mechanistic model for paradoxical platelet acti-
79. Leon MB, Baim DS, Popma JJ, et al: A clinical trial comparing three antithrombotic- vation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb
drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Vasc Biol 27(3):e9–e15, 2007.
Investigators. N Engl J Med 339(23):1665–1671, 1998. 108. Ferguson JJ, Kereiakes DJ, Adgey AA, et al: Safe use of platelet GP IIb/IIIa inhibitors.
80. Steinhubl SR, Berger PB, Mann JT 3rd, et al: Early and sustained dual oral antiplatelet Eur Heart J 19 Suppl D:D40–D51, 1998.
therapy following percutaneous coronary intervention: A randomized controlled trial. 109. Berkowitz SD, Sane DC, Sigmon KN, et al: Occurrence and clinical significance of
JAMA 288(19):2411–2420, 2002. thrombocytopenia in a population undergoing high-risk percutaneous coronary revas-
81. Bhatt DL, Fox KA, Hacke W, et al: Clopidogrel and aspirin versus aspirin alone for the cularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC)
prevention of atherothrombotic events. N Engl J Med 354(16):1706–1717, 2006. Study Group. J Am Coll Cardiol 32(2):311–319, 1998.
82. Lee GM, Welsby IJ, Phillips-Bute B, et al: High incidence of antibodies to protamine 110. Giugliano RP, McCabe CH, Sequeira RF, et al: First report of an intravenous and oral
and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary
Blood 121(15):2828–2835, 2013. syndromes: Results of the TIMI 15A and 15B trials. Am Heart J 140(1):81–93, 2000.
83. Bellemain-Appaix A, O’Connor SA, Silvain J, et al; ACTION Group: Association of 111. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after
clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibra-
among patients undergoing percutaneous coronary intervention: A systematic review fiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-
and meta-analysis. JAMA 308(23):2507–2516, 2012. acute Coronary Syndromes. Lancet 355(9201):337–345, 2000.
84. Parodi G, Storey RF: Dyspnoea management in acute coronary syndrome patients 112. Hongo RH, Brent BN: Association of eptifibatide and acute profound thrombocytope-
treated with ticagrelor. Eur Heart J Acute Cardiovasc Care 2014. [Epub ahead of print] nia. Am J Cardiol 88(4):428–431, 2001.
85. Alexopoulos D, Xanthopoulou I, Gkizas V, et al: Randomized assessment of ticagrelor 113. McClure MW, Berkowitz SD, Sparapani R, et al: Clinical significance of thrombocy-
versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial topenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein
infarction. Circ Cardiovasc Interv 5(6):797–804, 2012. IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT)
86. Franchi F, Rollini F, Muniz-Lozano A, et al: Cangrelor: A review on pharmacology and trial experience. Circulation 99(22):2892–2900, 1999.
clinical trial development. Expert Rev Cardiovasc Ther 11(10):1279–1291, 2013. 114. Abrams CS, Cines DB: Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia:
87. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators: Effect Possible link between platelet activation, autoimmunity and thrombosis. Thromb Hae-
of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med most 88(6):888–889, 2002.
368(14):1303–1313, 2013. 115. Christopoulos CG, Machin SJ: A new type of pseudothrombocytopenia: EDTA-
88. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in patients with mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J
acute coronary syndromes. N Engl J Med 361(11):1045–1057, 2009. Haematol 87(3):650–652, 1994.
89. Montalescot G, van ‘t Hof AW, Lapostolle F, et al; ATLANTIC Investigators: Prehospital 116. Sane DC, Damaraju LV, Topol EJ, et al: Occurrence and clinical significance of pseu-
ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371(11):1016– dothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36(1):75–83, 2000.
1027, 2014. 117. Ivy DD, Kinsella JP, Ziegler JW, Abman SH: Dipyridamole attenuates rebound pulmo-
90. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al: Protease-activated receptors 1 and nary hypertension after inhaled nitric oxide withdrawal in postoperative congenital
4 mediate activation of human platelets by thrombin. J Clin Invest 103(6):879–887, heart disease. J Thorac Cardiovasc Surg 115(4):875–882, 1998.
1999. 118. Gresele P, Arnout J, Deckmyn H, Vermylen J: Mechanism of the antiplatelet action of
91. Chackalamannil S, Xia Y, Greenlee WJ, et al: Discovery of potent orally active thrombin dipyridamole in whole blood: Modulation of adenosine concentration and activity.
receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. Thromb Haemost 55(1):12–18, 1986.
J Med Chem 48(19):5884–5887, 2005. 119. FitzGerald GA: Dipyridamole. N Engl J Med 316:1247, 1987.
92. Zhang C, Srinivasan Y, Arlow DH, et al: High-resolution crystal structure of human 120. Reilly M, FitzGerald GA: Gathering intelligence on antiplatelet drugs: The view from
protease-activated receptor 1. Nature 492(7429):387–392, 2012. 30 000 feet. When combined with other information overviews lead to conviction. BMJ
93. Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P–TIMI 50 Steering Committee 324(7329):59–60, 2002.
and Investigators: Vorapaxar in the secondary prevention of atherothrombotic events. 121. Diener HC, Cunha L, Forbes C, et al: European Stroke Prevention Study. 2. Dipyrida-
N Engl J Med 366(15):1404–1413, 2012. mole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143(1–
94. Goto S, Ogawa H, Takeuchi M, et al; J-LANCELOT (Japanese-Lesson from Antagoniz- 2):1–13, 1996.
ing the Cellular Effect of Thrombin) Investigators: Double-blind, placebo-controlled 122. Fisher CA, Kappa JR, Sinha AK, et al: Comparison of equimolar concentrations of ilo-
Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in prost, prostacyclin, and prostaglandin E1 on human platelet function. J Lab Clin Med
Japanese patients with acute coronary syndrome or high-risk coronary artery disease. 109(2):184–190, 1987.
Eur Heart J 31(21):2601–2613, 2010. 123. Fish KJ, Sarnquist FH, van Steennis C, et al: A prospective, randomized study of the
95. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular effects of prostacyclin on platelets and blood loss during coronary bypass operations.
medicine. N Engl J Med 332(23):1553–1559, 1995. J Thorac Cardiovasc Surg 91(3):436–442, 1986.
96. Bennett JS, Mousa S: Platelet function inhibitors in the Year 2000. Thromb Haemost 124. Sorkin EM, Markham A: Cilostazol. Drugs Aging 14(1):63–71; discussion 72–73, 1999.
85(3):395–400, 2001. 125. Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al: Systematic review and meta-
97. Hook KM, Bennett JS: Glycoprotein IIb/IIIa antagonists. Handb Exp Pharmacol analysis of randomized clinical trials appraising the impact of cilostazol after percuta-
2012(210):199–223, 1994. neous coronary intervention. Am Heart J 155(6):1081–1089, 2008.
98. French DL, Seligsohn U: Platelet glycoprotein IIb/IIIa receptors and Glanzmann’s 126. Khuri SF, Valeri CR, Loscalzo J, et al: Heparin causes platelet dysfunction and induces
thrombasthenia. Arterioscler Thromb Vasc Biol 20(3):607–610, 2000. fibrinolysis before cardiopulmonary bypass [see comments]. Ann Thorac Surg
99. Nurden AT: Inherited abnormalities of platelets. Thromb Haemost 82(2):468–480, 1999. 60(4):1008–1014, 1995.
100. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa 127. Sattler FR, Weitekamp MR, Ballard JO: Potential for bleeding with the new beta-lactam
receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med antibiotics. Ann Intern Med 105(6):924–931, 1986.
330(14):956–961, 1994. 128. Pillgram-Larsen J, Wisloff F, Jorgensen JJ, et al: Effect of high-dose ampicillin and
101. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose cloxacillin on bleeding time and bleeding in open-heart surgery. Scand J Thorac Cardio-
heparin during percutaneous coronary revascularization. N Engl J Med 336(24):1689– vasc Surg 19(1):45–48, 1985.
1696, 1997. 129. Fass RJ, Copelan EA, Brandt JT, et al: Platelet-mediated bleeding caused by broad-
102. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina spectrum penicillins. J Infect Dis 155(6):1242–1248, 1987.
and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syn- 130. Cazenave JP, Packham MA, Guccione MA, Mustard JF: Effects of penicillin G on plate-
drome Management in Patients Limited by Unstable Signs and Symptoms (PRISM- let aggregation, release, and adherence to collagen. Proc Soc Exp Biol Med 142(1):159–
PLUS) Study Investigators. N Engl J Med 338(21):1488–1497, 1998. 166, 1973.
103. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute cor- 131. Shattil SJ, Bennett JS, McDonough M, Turnbull J: Carbenicillin and penicillin G inhibit
onary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa platelet function in vitro by impairing the interaction of agonists with the platelet sur-
in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med face. J Clin Invest 65(2):329–337, 1980.
339(7):436–443, 1998. 132. Fletcher C, Pearson C, Choi SC, et al: In vitro comparison of antiplatelet effects of beta-
104. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al: First chronic platelet glyco- lactam penicillins. J Lab Clin Med 108(3):217–223, 1986.
protein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of 133. Packham MA, Rand ML, Perry DW, et al: Probenecid inhibits platelet responses to
xemilofiban in unstable angina with percutaneous coronary interventions. Circulation aggregating agents in vitro and has a synergistic inhibitory effect with penicillin G.
96(1):76–81, 1997. Thromb Haemost 76(2):239–244, 1996.

Kaushansky_chapter 121_p2073-2096.indd 2088 9/18/15 10:28 AM